Entera Bio Stock Alpha and Beta Analysis
| ENTX Stock | USD 1.57 0.20 11.30% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Entera Bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in Entera Bio over a specified time horizon. Remember, high Entera Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Entera Bio's market risk premium analysis include:
Beta (0.11) | Alpha (0.14) | Risk 4.71 | Sharpe Ratio (0.14) | Expected Return (0.66) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Entera Bio Backtesting, Entera Bio Valuation, Entera Bio Correlation, Entera Bio Hype Analysis, Entera Bio Volatility, Entera Bio History and analyze Entera Bio Performance. Entera Bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Entera Bio market risk premium is the additional return an investor will receive from holding Entera Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Entera Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Entera Bio's performance over market.| α | -0.14 | β | -0.11 |
Entera Bio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Entera Bio's Buy-and-hold return. Our buy-and-hold chart shows how Entera Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Entera Bio Market Price Analysis
Market price analysis indicators help investors to evaluate how Entera Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Entera Bio shares will generate the highest return on investment. By understating and applying Entera Bio stock market price indicators, traders can identify Entera Bio position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Parabolic SAR | ||
| MidPoint over period | ||
| Stalled Pattern | ||
| Separating Lines |
Entera Bio Return and Market Media
The median price of Entera Bio for the period between Thu, Oct 9, 2025 and Wed, Jan 7, 2026 is 2.33 with a coefficient of variation of 17.16. The daily time series for the period is distributed with a sample standard deviation of 0.4, arithmetic mean of 2.32, and mean deviation of 0.33. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Can Entera Bio Ltd. stock surprise with earnings upside - Market Risk Summary Expert Verified Movement Alerts - newser.com | 10/27/2025 |
2 | Can Entera Bio Ltd. stock expand revenue streams - Treasury Yields Long-Term Growth Plans - newser.com | 11/13/2025 |
3 | How Entera Bio Ltd. stock compares with market leaders - Market Volume Summary Weekly Momentum Stock Picks - newser.com | 11/19/2025 |
4 | Is Entera Bio Ltd. stock good for wealth creation - Earnings Trend Report Reliable Entry Point Trade Alerts - Newser | 12/04/2025 |
5 | Will Entera Bio Ltd. stock remain a Wall Street favorite - Analyst Upgrade Low Risk High Reward Ideas - DonanmHaber | 12/19/2025 |
6 | Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism | 12/22/2025 |
7 | H.C. Wainwright reiterates Buy rating on Entera Bio stock as FDA qualifies BMD endpoint - Investing.com | 12/24/2025 |
8 | Acquisition by Toledano Miranda Jayne of 11000 shares of Entera Bio at 1.8102 subject to Rule 16b-3 | 12/29/2025 |
9 | Acquisition by Taitel Haya of 33505 shares of Entera Bio at 1.94 subject to Rule 16b-3 | 12/31/2025 |
About Entera Bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Entera or other stocks. Alpha measures the amount that position in Entera Bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Payables Turnover | 1.17 | 1.14 | Days Of Inventory On Hand | 118.89 | 105.68 |
Entera Bio Upcoming Company Events
As portrayed in its financial statements, the presentation of Entera Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entera Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Entera Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Entera Bio. Please utilize our Beneish M Score to check the likelihood of Entera Bio's management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Entera Bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.